Literature DB >> 3790403

The effects of food and posture on the pharmacokinetics of a biphasic release preparation of nifedipine.

V Challenor, D G Waller, B S Gruchy, A G Renwick, C F George, E T McMurdo, J McEwen.   

Abstract

The pharmacokinetics of a novel 20 mg biphasic release tablet of nifedipine were compared with the conventional 10 mg capsule and 20 mg sustained release preparations in healthy volunteers. The influence of food and posture on the pharmacokinetics of the biphasic tablet were studied. In the fasting state, the time to peak concentration of nifedipine was not significantly different between the 20 mg biphasic and 20 mg sustained release tablets, but plasma concentrations were higher between 2 and 4 h after the biphasic tablet. The terminal elimination half-lives of the two formulations were similar. In subjects who fed prior to nifedipine administration there was no significant difference between either the peak plasma concentration or terminal half-life of the biphasic tablet and two 10 mg capsules of nifedipine. When the biphasic preparation was given after a standard breakfast, the time to peak plasma concentration was significantly longer and the terminal half-life shorter than when given in the fasting state. The dissolution characteristics of the biphasic tablet were influenced by prior administration of food to an extent which may be of clinical significance during twice daily administration.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3790403      PMCID: PMC1401174          DOI: 10.1111/j.1365-2125.1986.tb02936.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  15 in total

Review 1.  Drug kinetics and hepatic blood flow.

Authors:  C F George
Journal:  Clin Pharmacokinet       Date:  1979 Nov-Dec       Impact factor: 6.447

2.  The two-period cross-over clinical trial.

Authors:  M Hills; P Armitage
Journal:  Br J Clin Pharmacol       Date:  1979-07       Impact factor: 4.335

3.  Acute and long-term hypotensive effects and plasma concentrations of nifedipine in patients with essential hypertension.

Authors:  K Aoki; K Sato; Y Kawaguchi; M Yamamoto
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

4.  Antihypertensive and metabolic effects of long-term therapy with nifedipine slow-release tablets.

Authors:  K Landmark
Journal:  J Cardiovasc Pharmacol       Date:  1985 Jan-Feb       Impact factor: 3.105

5.  Nifedipine tablets for hypertension: a study using continuous ambulatory intra-arterial recording.

Authors:  R S Hornung; B A Gould; R I Jones; T Sonecha; E B Raftery
Journal:  Postgrad Med J       Date:  1983       Impact factor: 2.401

6.  Interim report of multicenter double-blind, placebo-controlled studies of nifedipine in chronic stable angina.

Authors:  H S Mueller; R A Chahine
Journal:  Am J Med       Date:  1981-10       Impact factor: 4.965

7.  Acute antihypertensive effect and pharmacokinetics of a tablet preparation of nifedipine.

Authors:  O Banzet; J N Colin; M Thibonnier; E Singlas; J M Alexandre; P Corvol
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

8.  Nifedipine kinetics and bioavailability after single intravenous and oral doses in normal subjects.

Authors:  T S Foster; S R Hamann; V R Richards; P J Bryant; D A Graves; R G McAllister
Journal:  J Clin Pharmacol       Date:  1983-04       Impact factor: 3.126

Review 9.  Influence of food intake on presystemic clearance of drugs.

Authors:  A Melander; A McLean
Journal:  Clin Pharmacokinet       Date:  1983 Jul-Aug       Impact factor: 6.447

10.  Objective assessment of antianginal treatment: a double-blind comparison of propranolol, nifedipine, and their combination.

Authors:  P Lynch; H Dargie; S Krikler; D Krikler
Journal:  Br Med J       Date:  1980-07-19
View more
  11 in total

Review 1.  Novel drug delivery systems. An overview of their impact on clinical pharmacokinetic studies.

Authors:  P S Banerjee; J R Robinson
Journal:  Clin Pharmacokinet       Date:  1991-01       Impact factor: 6.447

Review 2.  The combination of slow-release nifedipine and atenolol for stable angina.

Authors:  D G Waller; V F Challenor
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

3.  The influence of food on the pharmacokinetics of 'biphasic' nifedipine at steady state in normal subjects.

Authors:  G H Rimoy; J R Idle; N K Bhaskar; P C Rubin
Journal:  Br J Clin Pharmacol       Date:  1989-11       Impact factor: 4.335

Review 4.  Beta-adrenoceptor antagonists plus nifedipine in the treatment of chronic stable angina pectoris.

Authors:  V F Challenor; D G Waller; C F George
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

Review 5.  The influence of nutrition on the systemic availability of drugs. Part I: Drug absorption.

Authors:  I Walter-Sack
Journal:  Klin Wochenschr       Date:  1987-10-01

Review 6.  Sustained release nifedipine formulations. An appraisal of their current uses and prospective roles in the treatment of hypertension, ischaemic heart disease and peripheral vascular disorders.

Authors:  D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

7.  Slow release nifedipine plus atenolol in chronic stable angina pectoris.

Authors:  V F Challenor; D G Waller; A G Renwick; C F George
Journal:  Br J Clin Pharmacol       Date:  1989-11       Impact factor: 4.335

Review 8.  The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties.

Authors:  J S Grundy; R T Foster
Journal:  Clin Pharmacokinet       Date:  1996-01       Impact factor: 6.447

9.  The influence of posture on the pharmacokinetics of orally administered nifedipine.

Authors:  A G Renwick; C H Ahsan; V F Challenor; R Daniels; B S Macklin; D G Waller; C F George
Journal:  Br J Clin Pharmacol       Date:  1992-10       Impact factor: 4.335

Review 10.  Influence of posture on pharmacokinetics.

Authors:  Christian Queckenberg; Uwe Fuhr
Journal:  Eur J Clin Pharmacol       Date:  2008-10-21       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.